Mouse models have been a mainstay in biomedical research for decades. As these models have become more sophisticated, their application has grown and now includes a wide variety of immunodeficient strains that can be used to examine the in vivo growth of human tumors and to test new cancer treatments. One of the most popular models is the immunodeficient nonobese diabetic severe combined immunodeficiency (NOD scid) gamma (NSG) transgenic mouse line, which can be endowed with a humanized immune system using CD34+ hematopoietic stem cells. Next-generation NSG models that support human myeloid cell proliferation, such as the NSG-SGM3 mouse, can now provide in vivo conditions that better mimic the natural tumor environment. Human tumor tissue or cell lines can be coengrafted into these mouse models, providing a powerful tool for studying the interactions between human immune cells and human cancers. In this webinar we will discuss the latest advances in mouse models for cancer research and how they are being applied to help us understand the pathways and mechanisms involved in new immune therapies.
In this webinar the speakers will:
- Show comparisons of results from previous and current mouse models carrying reconstituted human immune systems
- Provide example data from experiments using PD-L1 positive tumors and a cancer cell-line engraftment into a humanized mouse model that was used to test anti-PD1 immune therapy
- Discuss how mouse models can be used to study human immune responses against leukemia (using primary or genetically modified leukemia cells) and melanoma
- Answer questions from the live online audience during the broadcast!
The webinar will last approximately 60 minutes.
To learn more about products or technologies related to this webinar, go to: jax.org/humanized-mice